63 publications

Name Date Type Actions

Vétoquinol markets CEFTIOCYL® and KEFLORIL® two new injectable antibiotics for livestock

Lure, December 15, 2010 – In line with recent announcements, Vétoquinol is
launching Ceftiocyl® and Kefloril®, two new injectable antibiotics for livestock.
The products are being brought to market by the Group and its subsidiaries in
both domestic and export markets.

 		15/12/2010 Public releases

Monthly information regarding the total number of voting rights and shares making of the share capital - November 2010

As per article 223.16 of the « Règlement Général de l’Autorité des Marchés Financiers »

 		07/12/2010 Voting rights

Programme de rachat - novembre 2010(french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

 		07/12/2010 Monthly communication regarding buyback programs


Vétoquinol appoints RÉGIS VIMAL DU MONTEIL Group Finance and Legal Director

November 30, 2010 (Lure, France) – Vétoquinol has appointed Régis Vimal du Monteil as
Group Legal and Financial Director.

 		30/11/2010 Public releases

Vétoquinol registers its injectable Marbocyl® 2% and Marbocyl® 10% antibiotics in Japan

November 18, 2010 (Lure, France) – Vétoquinol has just obtained Marketing
Authorisation (MA) from Japanese drug authorities for its Marbocyl® 2% and
Marbocyl® 10% antibiotics for livestock, through collaboration with Meiji Seika
Kaisha, Ltd.

 		18/11/2010 Public releases

Monthly information regarding the total number of voting rights and shares making of the share capital - October2010

As per article 223.16 of the « Règlement Général de l’Autorité des Marchés Financiers »

 		10/11/2010 Voting rights

Programme de rachat - octobre 2010(french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

 		10/11/2010 Monthly communication regarding buyback programs

Strong Sales in the 3rd Quarter of 2010

Vétoquinol’s revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group’s strategic regions and therapeutic segments.

 		19/10/2010 Public releases

Monthly information regarding the total number of voting rights and shares making of the share capital - September 2010

As per article 223.16 of the « Règlement Général de l’Autorité des Marchés Financiers »

 		08/10/2010 Voting rights

Programme de rachat - septembre 2010(french)

Tableau de déclaration mensuelle des opérations réalisées par un émetteur sur ses propres titres

 		08/10/2010 Monthly communication regarding buyback programs